Continuous Glucose Monitors (CGMs) have been a game changer for the type 1 diabetes community, becoming the standard of care for T1D. But all of these benefits can (and should) be applied to type 2 diabetes as well! Learn more at provider.dexcom.com

TCOYD and The diaTribe Foundation’s 3rd Virtual Diabetes Forum took place July 13th, 2022, and featured an impactful and sophisticated discussion on the cutting-edge developments in diabetes from key opinion leaders. These world-renown experts shared insights on the current state of diabetes care, and discussed ground-breaking research from the 2022 ADA Scientific Sessions.

Moderators: TCOYD’s Dr. Steven Edelman & diaTribe’s Kelly Close

Panelists:
Leslie Eiland, MD (Omaha)
James Gavin, MD (Fayetteville)
Jeremy Pettus, MD (San Diego)
William Polonsky, PhD, CDCES (San Diego)
Carolyn Wysham, MD (Spokane)

Topics Included:
• What we now know about COVID-19 and diabetes
• Updates on the ADA Standards of Care
• New data on cardiovascular and renal protection outcome studies: SGLT2 inhibitors and GLP1-RAs
• The changing landscape for the treatment of obesity
• The latest in hybrid closed loop systems including Tandem CIQ, Omnipod 5, Looping, and Medtronic 780G
• CGM updates including the Eversense 180 day, Dexcom G7 and FreeStyle Libre 3
• Updates on dual- and triple- agonists in development
• Smart pens and their impact on diabetes care
• Adjunctive therapies for T1D
• Next steps on multiple cures for T1D, particularly cell-based therapy
• Telehealth and its impact
• What will truly affect social determinants of health and health equity
• “Remission” for T2D

***NO LONGER AVAILABLE FOR CREDIT****

Telehealth has become an effective, efficient, and safe way to see diabetes patients during COVID, however it is here to stay for the long-term. We’ve assembled a group of expert faculty who have mastered the art of video visits and will take a deep dive into different telehealth methods you can implement to keep up with your patients even in the post-COVID period.

***NO LONGER AVAILABLE FOR CREDIT****

Coronary artery and chronic kidney disease are serious complications of diabetes that often lead to morbidity and mortality, as well as take a toll on the entire family. Making a significant impact involves not only prevention and early detection, but also aggressive management of both heart and kidney disease. In addition to discussing the basics of treating heart and kidney disease, we will do a deep dive into the cardiorenal effects of SGLT2 inhibitors and GLP1RAs to help you help your patients prevent, detect, and manage coronary artery and chronic kidney disease.